IDEXX Laboratories, Inc. $IDXX Shares Purchased by National Pension Service

Key Points

• The National Pension Service increased its stake in IDEXX Laboratories by 7.4%, now owning approximately 0.16% of the company valued at $53 million.
• IDEXX Laboratories reported better-than-expected earnings for the last quarter, with an EPS of $3.63, exceeding forecasts by $0.35, and revenue of $1.11 billion, up 10.6% year-over-year.
• Analysts have raised their ratings on IDEXX, with a consensus target price of $644.67 and a majority rating the stock as a "Moderate Buy."

National Pension Service raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,400 shares of the company's stock after buying an additional 8,752 shares during the quarter. National Pension Service owned about 0.16% of IDEXX Laboratories worth $53,082,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. MorganRosel Wealth Management LLC purchased a new stake in IDEXX Laboratories during the first quarter valued at approximately $26,000. Colonial Trust Co SC increased its holdings in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its position in IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after purchasing an additional 30 shares in the last quarter. Bank of Jackson Hole Trust grew its position in shares of IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after buying an additional 69 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its stake in shares of IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded down $0.8150 on Tuesday, hitting $637.0450. The company had a trading volume of 106,389 shares, compared to its average volume of 726,288. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market cap of $50.96 billion, a P/E ratio of 53.02, a price-to-earnings-growth ratio of 4.21 and a beta of 1.49. The company has a 50-day moving average price of $560.83 and a 200-day moving average price of $489.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. BTIG Research boosted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $649.44.

Insider Activity

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer owned 83,311 shares of the company's stock, valued at approximately $52,650,885.78. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,176 shares of company stock valued at $34,060,678 in the last ninety days. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.